Stem Cell-Derived Islet Therapy May Be Future Treatment Option For Patients With T1D
VX-880 is under development for the treatment of type I diabetes. It constitutes glucose-responsive, stem cell-derived beta (SCbeta) cells. It is an allogeneic human stem cell-derived islet cell therapy. It is infused into the hepatic portal vein.
Type 1 diabetes is characterized as the body’s abnormal immune system response, attacks and destroys the cells in the pancreas that make insulin. T1D patients usually presents with impaired hypoglycemic awareness and severe hypoglycemia, that often occurs because of imbalances between insulin administered relative to an individual’s requirements at a particular time that can be affected by a multitude of factors.
The study treated two patients with VX-880( one in Part A of the study who, per protocol, received half the target dose, and one in part B who received the full target dose) were treated for at least 12 months of follow-up.
The key findings of the trial are
-Both patients treated for more than 12 months are insulin independent; Patient A1 had HbA1c of 5.3% at Month 21 Patient B1 had HbA1c of 6.0% at Month 12 (compared to 7.6% at baseline).
-This level of glucose control is highly unusual in T1D patients treated with exogenous insulin, with recent data indicating that only approximately 25% of people with T1D meet the recommended HbA1c target of 7.0%.
-In fact, both patients displayed HbA1c levels that are below the diagnostic threshold for diabetes(6.5%).
ارسال به دوستان